88 Participants Needed

Etanercept for Tinnitus

Recruiting at 9 trial locations
JP
AS
JC
DB
RH
Overseen ByRobert Hong, MD/Ph.D.
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 3 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests if Etanercept injections can help adults with noise-induced tinnitus by reducing inflammation. The study aims to see if it can lower tinnitus distress and loudness, and improve hearing.

Will I have to stop taking my current medications?

The trial requires a four-week period without any other tinnitus treatments before starting. Some medications, like cyclophosphamide, sulfasalazine, and certain diabetes and immunomodulatory drugs, are not allowed during the study.

Is Etanercept generally safe for humans?

Etanercept has been shown to be generally safe in humans, with minor side effects like injection site reactions and upper respiratory infections. However, caution is advised as it may reactivate tuberculosis and there are concerns about a potential link to lymphoma.12345

How does the drug Etanercept differ from other treatments for tinnitus?

Etanercept is unique because it is a fusion protein that targets and binds to tumor necrosis factor-alpha (TNF-alpha), a molecule involved in inflammation, which is not a common approach for treating tinnitus. It is typically used for inflammatory conditions like rheumatoid arthritis, and its use for tinnitus is novel, as there are no standard treatments specifically targeting TNF-alpha for this condition.23456

What data supports the effectiveness of the drug Etanercept for treating tinnitus?

Etanercept has been shown to be effective in reducing inflammation in conditions like rheumatoid arthritis and psoriatic arthritis by blocking a protein called TNF-alpha, which is involved in inflammation. While there is no direct evidence for tinnitus, its success in other inflammatory conditions suggests potential benefits.34578

Who Is on the Research Team?

JZ

Jinsheng Zhang, Ph.D.

Principal Investigator

Wayne State University

Are You a Good Fit for This Trial?

Adults with moderate to severe tinnitus from noise or blast exposure, or associated with traumatic brain injury (TBI) or concussion. Participants must be stable enough psychologically for the study, not have used other tinnitus treatments in the last four weeks, and able to consent. All hearing levels are included but those with profound loss can't do certain tests.

Inclusion Criteria

Able to provide written informed consent.
People with any level of hearing ability can join the study. However, individuals with severe hearing loss won't be able to do certain hearing tests.
Able to provide written informed consent
See 31 more

Exclusion Criteria

I am not currently taking abatacept, cyclophosphamide, sulfasalazine, or similar medications.
You currently have a problem with drugs or alcohol.
I am a woman of child-bearing age not using contraception or I am breastfeeding.
See 16 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either Etanercept or placebo injections weekly

12 weeks
12 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Exploratory

Exploratory investigations to identify factors influencing therapeutic effects

36 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Etanercept
Trial Overview The trial is testing Etanercept (Enbrel), a medication given through injections, against a placebo (saline solution). The goal is to see if Etanercept can reduce the severity of tinnitus caused by loud noises or blasts. Participants will be randomly assigned to receive either Etanercept or placebo.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Etanercept Injection GroupExperimental Treatment1 Intervention
Group II: Placebo Injection GroupPlacebo Group1 Intervention

Etanercept is already approved in United States, European Union, Canada for the following indications:

๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as Enbrel for:
๐Ÿ‡ช๐Ÿ‡บ
Approved in European Union as Enbrel for:
๐Ÿ‡จ๐Ÿ‡ฆ
Approved in Canada as Enbrel for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Wayne State University

Lead Sponsor

Trials
318
Recruited
111,000+

University of Iowa

Collaborator

Trials
486
Recruited
934,000+

United States Naval Medical Center, San Diego

Collaborator

Trials
110
Recruited
24,200+

University of Miami

Collaborator

Trials
976
Recruited
423,000+

Michigan Ear Institute

Collaborator

Trials
1
Recruited
90+

Madigan Army Medical Center

Collaborator

Trials
52
Recruited
17,600+

Portland VA Medical Center

Collaborator

Trials
44
Recruited
7,800+

Published Research Related to This Trial

In a study of 43 patients with moderate to severe Crohn's disease, etanercept did not show significant efficacy compared to placebo, with only 39% of patients responding to treatment at week 4.
The safety profile of etanercept was similar to that of placebo, indicating that while it is safe to use, higher doses or more frequent administration may be necessary to achieve a therapeutic effect in Crohn's disease.
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.Sandborn, WJ., Hanauer, SB., Katz, S., et al.[2022]
Etanercept is a fusion protein that acts as a soluble receptor for tumor necrosis factor (TNF), effectively used to treat various chronic inflammatory diseases in humans, such as rheumatoid arthritis and psoriasis.
To study its effects in mouse models, researchers developed a murine version of the soluble p75-TNF receptor, allowing for better understanding of its mechanism in conditions that mimic human granulomatous infections.
Construction and purification of the murine p75-murine IgG1 fusion protein.Kim, HY., Renshaw-Gegg, LW., Balciunas, AM., et al.[2016]
In a study involving 12 patients with occupational medicamentosa-like dermatitis, treatment with etanercept significantly reduced the severity of the condition, as indicated by a decrease in the Drug Eruption Area and Severity Index (DASI) score from 56.33 to 0.50 after 4 weeks (P<0.01).
All patients achieved at least a 50% reduction in DASI score, and there were no reported adverse reactions, suggesting that etanercept is both effective and safe for treating this specific dermatitis.
[Recombinant human tumor necrosis factor receptor type โ…ก-IgG Fc fusion protein for treatment of occupational medicamentosa-like dermatitis induced by trichloroethylene].Lv, LL., Yan, ZH., Shi, X., et al.[2019]

Citations

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. [2022]
Construction and purification of the murine p75-murine IgG1 fusion protein. [2016]
[Recombinant human tumor necrosis factor receptor type โ…ก-IgG Fc fusion protein for treatment of occupational medicamentosa-like dermatitis induced by trichloroethylene]. [2019]
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. [2022]
Etanercept in arthritis. [2015]
Pharmacodynamic effects of the murine p75-Fc fusion protein in mice. [2016]
Etanercept and urticaria in patients with juvenile idiopathic arthritis. [2017]
Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. [2015]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity